|
Teicoplanin is an antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant ''Staphylococcus aureus'' and ''Enterococcus faecalis''. It is a semisynthetic glycopeptide antibiotic with a spectrum of activity similar to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis. Teicoplanin is marketed by Sanofi-Aventis under the trade name Targocid. Other trade names include Ticosin marketed by Cipla(India). Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and ''Clostridium difficile''-associated diarrhoea, with comparable efficacy with vancomycin. Its strength is considered to be due to the length of the hydrocarbon chain.〔 - includes picture of Teicoplanin's structure.〕 == Susceptibility data == Teicoplanin targets peptidoglycan synthesis making it an effective antimicrobial against Gram-positive bacteria including ''Staphylococci'' and ''Clostridium'' spp. The following represents MIC susceptibility data for a few medically significant pathogens: * ''Clostridium difficile'': 0.06 μg/ml - 0.5 μg/ml * ''Staphylococcus aureus'': ≤0.06 μg/ml - ≥128 μg/ml * ''Staphylococcus epidermidis'': ≤0.06 μg/ml - 32 μg/ml 〔http://www.toku-e.com/Assets/MIC/Teicoplanin.pdf〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Teicoplanin」の詳細全文を読む スポンサード リンク
|